Pharmerica revenue was $2.09 b in FY, 2016 which is a 3.1% year over year increase from the previous period.
Founding Date | 2007 |
Investors | KKR & Co. (Kohlberg Kravis Roberts & Co.) |
USD | FY, 2011 | FY, 2012 | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 |
---|---|---|---|---|---|---|
Revenue | 2.1b | 1.8b | 1.8b | 1.9b | 2.0b | 2.1b |
Revenue growth, % | 8% | 7% | 3% | |||
Cost of goods sold | 1.8b | 1.5b | 1.4b | 1.6b | 1.7b | 1.8b |
Gross profit | 293.3m | 300.2m | 327.2m | 339.3m | 335.1m | 326.0m |
Gross profit Margin, % | 14% | 16% | 19% | 18% | 17% | 16% |
R&D expense | 3.0m | |||||
General and administrative expense | 214.9m | 214.7m | 225.3m | 236.3m | 222.5m | 220.6m |
Operating expense total | 246.3m | 251.4m | 271.4m | 308.9m | 281.3m | 287.6m |
Depreciation and amortization | 15.4m | 20.1m | 28.6m | 33.7m | ||
EBIT | 47.0m | 48.8m | 55.8m | 30.4m | 53.8m | 38.4m |
EBIT margin, % | 2% | 3% | 3% | 2% | 3% | 2% |
Interest expense | 8.8m | 10.0m | 10.6m | 9.9m | 6.6m | 9.5m |
Pre tax profit | 38.2m | 38.8m | 45.2m | 16.2m | 47.2m | 28.9m |
Income tax expense | 14.8m | 15.9m | 26.3m | 9.4m | 12.1m | 7.3m |
Net Income | 23.4m | 22.9m | 18.9m | 6.8m | 35.1m | 21.6m |
USD | FY, 2011 | FY, 2012 | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 |
---|---|---|---|---|---|---|
Cash | 17.4m | 12.3m | 24.2m | 33.3m | 23.1m | 5.4m |
Accounts Receivable | 232.4m | 206.5m | 199.8m | 195.7m | 200.5m | 235.4m |
Prepaid Expenses | 34.5m | 38.6m | 38.6m | 90.4m | 52.4m | |
Inventories | 130.5m | 135.7m | 110.3m | 135.7m | 155.2m | 214.7m |
Current Assets | 451.3m | 429.8m | 411.7m | 497.3m | 483.5m | 552.4m |
PP&E | 53.1m | 61.9m | 71.4m | 74.5m | ||
Goodwill | 214.2m | 268.2m | 282.6m | 317.7m | 371.0m | 392.3m |
Total Assets | 833.4m | 885.7m | 901.4m | 1.1b | 1.2b | 1.3b |
Accounts Payable | 54.1m | 49.2m | 83.8m | 95.5m | 71.7m | 107.1m |
Short-term debt | 6.3m | 12.5m | 12.5m | 18.0m | 11.6m | 15.6m |
Current Liabilities | 102.2m | 106.5m | 151.5m | 175.8m | 141.4m | 182.3m |
Long-term debt | 293.7m | 303.0m | 218.8m | 344.9m | 415.7m | 457.8m |
Total Debt | 300.0m | 315.5m | 231.3m | 351.3m | 427.3m | 473.4m |
Common Stock | 300.0k | 300.0k | 300.0k | 300.0k | 300.0k | |
Preferred Stock | ||||||
Additional Paid-in Capital | 355.9m | 363.0m | 380.2m | 394.1m | 404.6m | 411.1m |
Retained Earnings | 68.4m | 91.3m | 110.2m | 117.0m | 152.1m | 173.7m |
Total Equity | 413.8m | 442.6m | 462.5m | 478.1m | 519.4m | 544.2m |
Debt to Equity Ratio | 0.7 x | 0.7 x | 0.5 x | 0.7 x | 0.8 x | 0.9 x |
Debt to Assets Ratio | 0.4 x | 0.4 x | 0.3 x | 0.3 x | 0.4 x | 0.4 x |
Financial Leverage | 2 x | 2 x | 1.9 x | 2.2 x | 2.2 x | 2.4 x |
USD | FY, 2011 | FY, 2012 | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 |
---|---|---|---|---|---|---|
Net Income | 23.4m | 22.9m | 18.9m | 6.8m | 35.1m | 21.6m |
Depreciation and Amortization | 20.1m | 18.6m | 40.4m | 51.7m | 57.5m | |
Accounts Receivable | 9.1m | 35.8m | 29.1m | (2.4m) | (34.3m) | |
Inventories | (38.3m) | (4.7m) | (18.8m) | (15.9m) | (56.7m) | |
Accounts Payable | (25.0m) | (9.3m) | (2.9m) | (24.0m) | 36.4m | |
Cash From Operating Activities | 26.8m | 85.7m | 48.4m | 18.5m | 30.8m | |
Purchases of PP&E | (51.0m) | (20.8m) | (26.5m) | (25.6m) | (23.9m) | (34.2m) |
Capital Expenditures | (13.2m) | |||||
Cash From Investing Activities | (64.0m) | (105.3m) | (157.0m) | (104.1m) | (91.7m) | |
Long-term Borrowings | (240.0m) | (6.3m) | (231.3m) | (5.5m) | (11.3m) | |
Cash From Financing Activities | 43.8m | 14.5m | 117.7m | 75.4m | 43.2m | |
Net Change in Cash | 6.6m | (5.1m) | 9.1m | (10.2m) | (17.7m) | |
Interest Paid | 7.6m | 9.3m | 8.5m | 10.6m | ||
Income Taxes Paid | 500.0k | 12.6m | 19.4m | (4.8m) | ||
Free Cash Flow | 13.6m |
USD | Q2, 2011 |
---|---|
Debt/Equity | 0.7 x |
Debt/Assets | 0.3 x |
Financial Leverage | 2.1 x |